Questcor HP Acthar
Executive Summary
Questcor plans to ship HP Acthar gel in September following acquisition of the andrenocorticotropic hormone gel from Aventis. The National Organization for Rare Disorders has administered a patient access program for Acthar since 1996 due to limited availability of the product; Questcor expects to resume normal distribution of Acthar in the fall. Aventis will continue to manufacture Acthar for two to three years while production is transitioned to a new manufacturer. Acthar is approved for acute exacerbations of multiple sclerosis but is commonly used off-label to treat infantile spasms. Questcor will use its 19-rep sales force to promote Acthar to the approximately 900 pediatric neurologists in the U.S
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth